Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
Dove Medical Press (Taylor and Francis Group) · 2026-05-28
Arterial and venous thromboembolic events in <i>ALK</i> - and <i>ROS1</i> -positive non–small cell lung cancer (NSCLC): A multicenter real-world analysis.
Journal of Clinical Oncology · 2026-05-28
PP01.63: Surgery in Previously Unresectable Stage IV Driver Mutation Lung Adenocarcinoma Patients After Targeted Therapy: A Single Center Experience
Journal of Thoracic Oncology · 2026-05-01
PP01.36: Efficacy and Safety of Pralsetinib in Patients with Advanced RET Fusion-Positive NSCLC from the United States: A Sub-Analysis of the ARROW Trial
Journal of Thoracic Oncology · 2026-05-01
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
Lung Cancer Targets and Therapy · 2026-05-01
“Whack-a-Mole” Treatment Approach to 3G EGFR TKI Progression: Elegant Translational Science but Limited Clinical Applicability?
Journal of Thoracic Oncology · 2026-02-01
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2025-12-11
Harmonizing the DESTINY and Broadening the HORIZON of HER2 ADCs in the Face of Next-Generation HER2 TKI for the Treatment Options of HER2 mutations positive (HER2+) NSCLC
Journal of Thoracic Oncology · 2025-12-01
Supplementary Tables1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025-12-01
Suppl Figures 1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025-12-01
Supplemental Figure 3 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
2025-11-25
Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
2025-11-25
Supplemental Figure 4 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
2025-11-25
Supplemental Figure 2 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
2025-11-25
Supplemental Figure 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
2025-11-25
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Journal of the National Comprehensive Cancer Network · 2025-11-19
Clinical Application Effect of Ciprofol Combined with Low-dose Esketamine in Painless Gastrointestinal Endoscopy
Journal of Clinical and Nursing Research · 2025-11-13
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Clinical Cancer Research · 2025-10-07 · 6 citations
P1.11.70 Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual ICI or ICI-Chemotherapy
Journal of Thoracic Oncology · 2025-10-01
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
Lung Cancer Targets and Therapy · 2025-10-01 · 1 citations